Skip to content
Screener

Cumulative Cost Basis at other companies

Amgen logo
AmgenAMGN
$13.42B+79.2%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$776M-16.3%
Incyte logo
IncyteINCY
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
PTH
Pelthos TherapeuticsPTHS
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Revenue$129.9M+59.3%
Gross profit$118.9M+60.7%
Operating income$16.4M+212%
Net income$15.0M+194%
EPS (diluted)$0.11+185%

Balance sheet

See full
Cash & equivalents$34.4M-52.9%
Total debt$114.1M+3.6%
Total equity$220.6M+58.7%
Total assets$488.5M+38.6%

Cash flow

See full
Operating cash flow$12.6M
CapEx$158.0K+103%
Free cash flow$12.5M

Valuation

See full
Market cap$3.32B+81.4%
Enterprise value$3.4B+82.1%
P/S7.2×+0.2×

Profitability

See full
Gross margin91.1%+2.0pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.5×-0.3×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001787306-26-000051
Line itemAmortizedcostUnrealizedgainsUnrealizedlossesEstimatedfair value
Money market funds and cash$28,658$28,658
Certificates of deposit5,4635,463
Total cash and cash equivalents$34,121$34,121
Marketable securities:
Commercial paper$16,584$(17)$16,567
Corporate debt securities94,3251(192)94,134
U.S. Treasury and agency securities93,856(126)93,730
Total marketable securities$204,765$1$(335)$204,431

Item 1. Financial Statements (Unaudited)

FAQ

What is Arcutis Biotherapeutics, Inc.'s cumulative cost basis?
Arcutis Biotherapeutics, Inc. (ARQT) reported cumulative cost basis of $204.77M in Q2 2026.
How has Arcutis Biotherapeutics, Inc.'s cumulative cost basis changed year-over-year?
Arcutis Biotherapeutics, Inc.'s cumulative cost basis increased by 73.5% year-over-year, from $118M to $204.77M.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s cumulative cost basis?
Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s cumulative cost basis has grown at a -4.1% compound annual growth rate (CAGR), from $219.36M to $177.96M.
What does cumulative cost basis mean?
The aggregate historical cost basis of assets or liabilities before adjustments for fair value, impairment, or amortization.

Ask your AI about Arcutis Biotherapeutics, Inc.'s cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude